Related Experiment Videos
Alzheimer's disease: targets for drug development
1Cognitive Function Clinic, Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, Liverpool, L9 7LJ, UK. larner-a@wcnn-tr.nwest.nhs.uk
Mini Reviews in Medicinal Chemistry
|October 9, 2002
Summary
Recent Alzheimer's disease (AD) research highlights new therapeutic targets. This overview focuses on amyloid beta-peptides and tau protein as key areas for AD treatment development.
Area of Science:
- Neurobiology
- Pharmacology
- Neurology
Background:
- Alzheimer's disease (AD) pathogenesis involves complex neurobiological mechanisms.
- Significant advancements in understanding AD have occurred over the last 15 years.
- Identifying novel therapeutic targets is crucial for effective AD treatment.
Purpose of the Study:
- To provide a comprehensive overview of potential therapeutic targets for Alzheimer's disease.
- To emphasize targets related to amyloid beta-peptides and tau protein.
- To inform researchers and clinicians about the current landscape of AD drug development.
Main Methods:
- Literature review of recent neurobiological studies on Alzheimer's disease.
- Analysis of therapeutic strategies targeting key pathological hallmarks of AD.
- Synthesis of information on amyloid beta-peptides and tau protein as primary targets.
Main Results:
- Numerous potential therapeutic targets for AD have emerged from recent neurobiological research.
- Amyloid beta-peptides and tau protein represent prominent targets for intervention.
- The spectrum of targets spans various molecular and cellular pathways involved in AD.
Conclusions:
- Targeting amyloid beta-peptides and tau protein holds significant promise for Alzheimer's disease treatment.
- Continued research into neurobiology is essential for discovering innovative AD therapies.
- A multifaceted approach targeting various pathways may be necessary for effective AD management.